Open Access Full Text Article

RETRACTION

Metformin Decreases Insulin Resistance in Type I Diabetes Through Regulating P53 and RAP2A in vitro and in vivo [Retraction]

Ren GF, Xiao LL, Ma XJ, Yan YS, Jiao PF. Drug Des Devel Ther. 2020:14;2381–2392.

The Editor-in-chief and Publisher of *Drug Design*, *Development and Therapy* wish to retract the published article. The journal was notified of alleged image manipulation relating to the western blot images presented in the article. Specifically:

- The background of the western blot images shown in Figure 2C panels p53 and RAP2A appear to show repeated features.
- The background of the western blot image shown in Figure 2C panel β-actin appears to show repeated features.
- The background of the western blot images shown in Figure 3A panels IR3K, p-PI3K and p-Akt appear to show repeated features.
- The background of the western blot image shown in Figure 3A panel β-actin appears to show repeated features.
- The background of the western blot images shown in Figure 3B panels IR3K, p-PI3K and p-Akt appear to show repeated features.
- The background of the western blot images shown in Figure 4A panels Caspase 3, Caspase 9, Bax and Bcl2 appear to show repeated features.

- The background of the western blot images shown in Figure 4B panels Caspase 3, Caspase 9, Bax and Bcl2 appear to show repeated features.
- The background of the western blot images shown in Figure 5A panels NF- κ B p65, TNF- α , IL-8 and IL-6 appear to show repeated features.
- The background of the western blot images shown in Figure 5A panel β-actin appears to show repeated features.
- The background of the western blot images shown in Figure 5B panels NF-κB p65, TNF-α, IL-8 and IL-6 appear to show repeated features.

Despite multiple attempts the authors were unable to be contacted and could not provide an explanation for the alleged duplication. The decision was made to retract the paper.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

Drug Design, Development and Therapy

Publish your work in this journal

Drug Design, Development and Therapy is an international, peerreviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/drug-design-development-and-therapy-journal

https://doi.org/10.2147/DDDT.S322990

terms.php and incorporate the Greative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/license/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).



Dovepress